RE:RE:Th1902- I think you are right to say there is no rush to restart oncology. With that in mind there's probably also no rush to go public on the path forward. I don't think what Christian is saying today is pinpointing the problem. It's broad possibilities. If you know you aren't starting soon then why not take all the time to dive into the problem and find the answers. Why at this early point commit to one particular cause and solution? I don't think you should think the statements they make now are necessarily where they will be in 6 months time. He offering broad possibilities now, they will probably need to narrow that down before it becomes meaningful. I'd take these statements with a pinch of salt for now.
SPCEO1 wrote: Yes, but it seems like it is a 2024 story as the objective of getting to cash flow positive this year probably negates any significant spending on TH-1902 this year. Hopefully, the new effort to target healthier patients and tumors where TH-1902 has already shown activity with smaller, more frequent doses will be accepted by the FDA and will work.